Throughput is a grant constraint.Treat it like one.
For a core facility, analysis time is cost and queue depth is a planning problem. Faster runs on comparably-priced hardware mean more samples per grant dollar.
01 · What changes
Three practical differences.
Cost per genome falls with wall clock. F2 instances are priced comparably to the CPU instances they replace, so compressing the run compresses the bill. Cost estimates are shown before submission, and an organisation can set a hard spend cap.
Reproducibility is automatic. Pipelines are digest-pinned and analyses are immutable, so the methods section of a paper can cite an exact pipeline version, and a reviewer can be given the same one.
Collaborators cost nothing to add. Read-only seats are free on every plan, so a collaborating lab or a supervising PI is never a licensing decision.
02 · Honest fit
When GenoAccel is not the right answer yet.
If you need results for clinical reporting today, the gating requirement is CLIA certification held by the reporting laboratory, and our clinical surfaces are a later phase. Research and method-development use is unaffected.
If your bottleneck is primary analysis or basecalling, GenoAccel does not address it — we begin at FASTQ.
If you have fewer than a handful of genomes a year, the platform fee is unlikely to pay for itself against an existing institutional cluster allocation. We would rather say so than sell you a subscription you will not use.